↓ Skip to main content

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)

Overview of attention for article published in BMC Rheumatology, February 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
Published in
BMC Rheumatology, February 2018
DOI 10.1186/s41927-018-0010-2
Pubmed ID
Authors

Athimalaipet V. Ramanan, Andrew D. Dick, Ashley P. Jones, Catherine Guly, Ben Hardwick, Helen Hickey, Richard Lee, Andrew McKay, Michael W. Beresford

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 15%
Other 4 12%
Researcher 4 12%
Student > Postgraduate 4 12%
Professor > Associate Professor 4 12%
Other 7 21%
Unknown 6 18%
Readers by discipline Count As %
Medicine and Dentistry 17 50%
Nursing and Health Professions 3 9%
Immunology and Microbiology 2 6%
Agricultural and Biological Sciences 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 2 6%
Unknown 8 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2019.
All research outputs
#8,856,458
of 14,634,562 outputs
Outputs from BMC Rheumatology
#54
of 85 outputs
Outputs of similar age
#152,801
of 273,858 outputs
Outputs of similar age from BMC Rheumatology
#1
of 2 outputs
Altmetric has tracked 14,634,562 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 85 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,858 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them